Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 9.8% – Should You Buy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price shot up 9.8% during trading on Friday . The company traded as high as $29.44 and last traded at $28.7670. 887,835 shares changed hands during trading, a decline of 59% from the average session volume of 2,153,484 shares. The stock had previously closed at $26.19.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on CAPR shares. Maxim Group boosted their target price on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Alliance Global Partners reiterated a “buy” rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. Industrial Alliance Securities set a $48.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Capricor Therapeutics in a research note on Monday. Finally, Oppenheimer boosted their price target on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Capricor Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $40.82.

Capricor Therapeutics Trading Up 6.7%

The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -15.61 and a beta of 0.61. The business’s fifty day simple moving average is $11.08 and its 200 day simple moving average is $9.29.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, hitting analysts’ consensus estimates of ($0.54). As a group, research analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CAPR. Charles Schwab Investment Management Inc. raised its stake in Capricor Therapeutics by 2.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 113,650 shares of the biotechnology company’s stock worth $1,079,000 after acquiring an additional 2,314 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Capricor Therapeutics by 122.2% during the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after buying an additional 2,786 shares during the last quarter. Deutsche Bank AG lifted its stake in shares of Capricor Therapeutics by 10.9% in the 1st quarter. Deutsche Bank AG now owns 28,699 shares of the biotechnology company’s stock valued at $272,000 after purchasing an additional 2,822 shares during the period. Legal & General Group Plc grew its position in shares of Capricor Therapeutics by 8.4% during the 2nd quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock worth $410,000 after buying an additional 3,205 shares during the period. Finally, Rhumbline Advisers grew its stake in shares of Capricor Therapeutics by 7.3% in the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock valued at $531,000 after buying an additional 3,636 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.